Fibrin‐Targeting Metal–Organic Framework Nanoagent for NIR‐Triggered Photothermal Thrombus Ablation
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202503394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Yu-Liang Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, National Taiwan University, Taipei, 10617, Taiwan. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Thrombosis, Fibrin, Photothermal Therapy. Die Arbeit nennt 90 Literaturangaben. Gefördert von: National Science and Technology Council, Taiwan, National Science and Technology Council.
Abstract (Originalsprache)
Thrombosis remains a leading cause of mortality worldwide; however, current thrombolytic therapies suffer from limited thrombus targeting, poor penetration, and systemic side effects. To address these challenges, a fibrin‐targeting photothermal nanoassembly, GCREKA‐Pd@MIL‐100, is engineered by encapsulating ultrasmall palladium (Pd) nanoclusters into a MIL‐100(Fe) metal–organic framework and grafting a stabilized peptide ligand Gly–Cys–Arg–Glu–Lys–Ala (GCREKA) onto its surface. The porous MIL‐100 matrix provides spatial confinement for the Pd nanoclusters, yielding uniform localized surface plasmon resonance (LSPR) active domains with high near‐infrared (NIR) photothermal conversion efficiency. Covalent functionalization with GCREKA enhances colloidal stability and thrombus affinity. In vitro studies demonstrate that GCREKA‐Pd@MIL‐100 exhibits excellent cytocompatibility and hemocompatibility while achieving a clot mass reduction of over 50% under NIR irradiation. In a FeCl 3 ‐induced mouse mesenteric thrombosis model, GCREKA‐Pd@MIL‐100 accumulates selectively at the thrombotic site accompanied by localized heat (>60 °C) generation and achieves ≈60% thrombus clearance without off‐target tissue damage. These findings highlight that GCREKA‐Pd@MIL‐100 is a potent site‐specific nanoagent for minimally invasive thrombolysis, offering a promising alternative to conventional thrombolytic therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Engineering, National Taiwan University, Taipei, 10617, Taiwan.
- Department of Biochemical and Molecular Medical Sciences, National Dong Hwa University, Hualien, 974301, Taiwan.
- Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University, Taipei, 11031, Taiwan.
- Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli, 350401, Taiwan.
- Department of Chemical Engineering and Materials Science, Yuan-Ze University, Taoyuan, 32003, Taiwan.
ORCID-Profile: Jiashing Yu
Förderung
- National Science and Technology Council, Taiwan
- National Science and Technology Council
Zitieren
APA
Chen, Y. L., Liu, M. H., Hsieh, M. F., Liang, Y. Y., Lin, C. W., Chuang, E. Y., Wu, K. C., & Yu, J. (2026). Fibrin‐Targeting Metal–Organic Framework Nanoagent for NIR‐Triggered Photothermal Thrombus Ablation. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503394
Vancouver
Chen YL, Liu MH, Hsieh MF, Liang YY, Lin CW, Chuang EY, et al. Fibrin‐Targeting Metal–Organic Framework Nanoagent for NIR‐Triggered Photothermal Thrombus Ablation. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503394
BibTeX
@article{Chen2026,
author = {Chen, Yu-Liang and Liu, Ming-Hsin and Hsieh, Ming-Feng and Liang, Yung-Yi and Lin, Che-Wei and Chuang, Er-Yuan and Wu, Kevin C-W and Yu, Jiashing},
title = {Fibrin‐Targeting Metal–Organic Framework Nanoagent for NIR‐Triggered Photothermal Thrombus Ablation},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202503394}
}
EUVIMED